(Reuters) – New Danish pharmacist Nordisk has guaranteed global rights to develop, manufacture and sell the united laboratories international weight loss candidate in a business of up to $ 2 billion.
As part of the agreement with a United Lab unit announced on Monday, Novo will make an initial payment of $ 200 million and up to $ 1.8 billion after the completion of certain development and sales milestones for the drug called UBT251.
Novo, which is one of the main participants in the growing global obesity treatment market, has been trying to strengthen its position in this space through the development of state -of -the -art medicines, acquisitions and partnerships.
Last year, rival Eli Lilly also joined a China -based biotechnology company to develop an obesity drug that aims to help patients lose weight and at the same time preserve their muscles.
United Lab’s UBT251 targets a total of three hormones, compared to Wegovy, the new medication of the new for weight loss, which targets only GLP-1, which mimics an intestinal hormone that helps control blood sugar levels and slow digestion, causing people to feel more time.
The drug target of the agreement announced on Monday is in the early development stages and being tested on people with obesity in mainland China, United Lab said.
Continues after advertising
New is also developing a drug for next -generation obesity, Cagrisema, which expects to be a more powerful Wegovy successor and help gain advantage over Lilly.
